Skip to main content
. 2021 Sep 23;22(19):10255. doi: 10.3390/ijms221910255

Figure 3.

Figure 3

Effect of combination therapy using DFMO and cisplatin on SKOV-3 cell survival and apoptotic cell death. Cell viability was determined of cells treated with (A) 10 μM cisplatin, 100 μM DFMO, or (B) 10 μM cisplatin/0–100 μM DFMO for 48 h using the PrestoBlue assay and CellTiter-Glo assay. (C) Proliferation was determined in cells treated with (C) 10 μM cisplatin, 100 μM DFMO, or (D) 10 μM cisplatin/0–100 μM DFMO for 48 h. (E) Flow cytometric analysis of Annexin V-FITC/PI-stained SKOV-3 cells treated with 10 μM cisplatin/0–100 μM DFMO for 48 h was performed to determine the apoptotic rates of SKOV-3 cells under various concentrations of DFMO. (F) Caspase-3 activity in cisplatin/DFMO-treated SKOV-3 cells was measured using the Luciferase Assay (Caspase-Glo 3/7 Assay system). (G) Western blot and quantification analysis for the apoptotic proteins Bcl-2, Bcl-xL, Bax, cleaved caspase-3, and cleaved PARP in cells treated with DFMO. The controls were treated with 0.1% DMSO. Data are expressed as mean ± SD. ** p < 0.01, *** p < 0.001 compared with the controls.